Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bridgewater, New Jersey 08807


Purpose:

An open-label study to determine the efficacy and safety of Rasburicase used for the prevention and treatment of tumor lysis syndrome


Criteria:

Inclusion Criteria: - Chemotherapy planned for at least 3 cycles - Undergoing cytoreductive chemotherapy for ALL, multiple myeloma or Burkitt's lymphoma stage III or IV - With a minimum life expectancy of 3 months - Uric acid > 8 mg% - Negative pregnancy test < or =to 2 weeks and efficient contraceptive method. - Negative HIV serology < or =to 4 weeks - Patient or legal guardian has signed a written informed consent Exclusion Criteria: - Hypersensitivity to uricases or any of the excipients - Known history of G6PD deficiency. - Previous treatment with Rasburicase or Uricozyme® - Pregnancy or lactation - Treatment with any investigational drug within 30 days before planned first Rasburicase administration


NCT ID:

NCT00651911


Primary Contact:

Study Director
Sharon Chang
Sanofi-Aventis


Backup Contact:

N/A


Location Contact:

Bridgewater, New Jersey 08807
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.